Good morning, everyone, and how are you today? We are doing just fine, thank you, despite the frenzied atmosphere here at the biopharma Woodstock. The trick is to keep moving and quaff repeated cups of stimulation. Perhaps you relate. In any event, here are some tidbits to keep you going. Hope your day is successful and drop us a line if you hear anything interesting …

The U.S. Senate Finance Committee will hold a hearing on Tuesday morning at 10 a.m. ET to decide whether to endorse Alex Azar, a former Eli Lilly (LLY) executive, as the next secretary of the U.S. Department of Health and Human Services. His nomination has cheered drug makers, but angered industry critics for various reasons, including steep price hikes on insulin that he oversaw while working at Lilly.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • One word of advice for the Pharmalot Aquarians at Biopharma Woodstock: “Stay away from the brown acid.”
    Chip Moncke

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy